2Platts-Mills T A,Rakes G,Heymann P W.The relevance of allergen exposure to the development of asthma in childhood. J Allergy Clin Immunol,2000,105:S503-508.
3Wilson D R,Merrett T G,Varga E M,et al.Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med,2002,165:22-26.
4Breedveld F C.Therapeutic monoclonal antibodies. Lancet,2000,355:735-740.
5Chang T W.The pharmacological basis of anti-IgE therapy. Nat Biotechnol,2000,18:157-162.
6Schulman E S.Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.Am J Respir Crit Care Med,2001,164:S6-S11.
7Saini S S, Klion A D,Holland S M,et al.The relationship between serum IgE and surface levels of FcepsilonR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol,2000,106:514-520.
8Froehlich J, Schoenhoff M, Tremblay T, et al. Initial human study with a humanized recombinant anti-IgE monoclonal anti-body: safety, tolerance and pharmacokinetic (PK)/dynamic profile.Clin Pharmacol Ther,1995,57:162-162.
9Casale T, Bernstein I L,Busse W W,et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Iummunol,1997,100:110-121.
10Casale T B, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA,2001,286:2956-2967.
